Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
Sponsor: International Collaborative Cancer Group
A PHASE3 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by International Collaborative Cancer Group and has accumulated 9 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- International Collaborative Cancer Group
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark , Adelaide, Australia , Alba (CN), Italy , Albacete, Spain , Albany, United States , Alcoy, Spain , Alicante, Spain , Amersfoort, Netherlands , Amsterdam, Netherlands , Angers, France and 308 more locations